Bladder Cancer Photodynamic Therapeutic Agent with Off‐On Magnetic Resonance Imaging Enhancement

Chen Xie,Ho‐Fai Chau,Jing‐Xiang Zhang,Sheng Tong,Lijun Jiang,Wan‐Yiu Fok,Hong‐Lok Lung,Shuai Zha,Rui Zou,Ju Jiao,Chi‐Fai Ng,Ping'an Ma,Junhui Zhang,Jun Lin,Kwok Keung Shiu,Jean‐Claude G. Bünzli,Wai‐Kwok Wong,Nicholas J. Long,Ga‐Lai Law,Ka‐Leung Wong
DOI: https://doi.org/10.1002/adtp.201900068
IF: 5.003
2019-08-16
Advanced Therapeutics
Abstract:Acting as an extracellular matrix protein receptor, αVβ3 integrin becomes an appealing target for photodynamic therapy of bladder cancer. Here, specific αVβ3‐integrin‐targeting porphyrinato‐gadolinium complexes (Gd‐PEG‐Rn) are demonstrated as off‐on theranostic agents, where Rn are specific peptides. Among them, Gd‐PEG‐R3 shows both impressive phototherapeutic index and robust in vivo magnetic resonance imaging (MRI) signal enhancement. Significant selectivity of Gd‐PEG‐R3 is proven by its high αVβ3 integrin binding affinity in positive bladder cancer cells. All these findings support Gd‐PEG‐R3 as a promising bi‐functional medical agent with both MRI contrasting ability and photodynamic therapeutic potential for curing bladder cancer. Gadolinium‐based porphyrin complexes, after conjugating with bladder‐cancer‐specific peptides, show both diagnostic and therapeutic effects simultaneously: the complexes have increasing relaxivity after binding with targets and help improve magnetic resonance imaging quality; photodynamic therapy can also be achieved by light trigger and singlet oxygen generation afterward with high selectivity to bladder cancers.
What problem does this paper attempt to address?